PL2354134T3 - Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny - Google Patents

Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny

Info

Publication number
PL2354134T3
PL2354134T3 PL09830473T PL09830473T PL2354134T3 PL 2354134 T3 PL2354134 T3 PL 2354134T3 PL 09830473 T PL09830473 T PL 09830473T PL 09830473 T PL09830473 T PL 09830473T PL 2354134 T3 PL2354134 T3 PL 2354134T3
Authority
PL
Poland
Prior art keywords
sphingosine
stimulators
phosphate receptor
chromene derivatives
chromene
Prior art date
Application number
PL09830473T
Other languages
English (en)
Inventor
Hironori Harada
Kazuyuki Hattori
Kazuya Fujita
Sunao Imada
Tatsuaki Morokata
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL2354134T3 publication Critical patent/PL2354134T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
PL09830473T 2008-12-05 2009-12-04 Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny PL2354134T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008311445 2008-12-05
PCT/JP2009/070398 WO2010064707A1 (ja) 2008-12-05 2009-12-04 ２ｈ－クロメン化合物及びその誘導体
EP09830473.6A EP2354134B1 (en) 2008-12-05 2009-12-04 2h-chromene derivatives as stimulators of sphingosine 1-phosphate receptor

Publications (1)

Publication Number Publication Date
PL2354134T3 true PL2354134T3 (pl) 2016-07-29

Family

ID=42233354

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09830473T PL2354134T3 (pl) 2008-12-05 2009-12-04 Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny

Country Status (15)

Country Link
US (2) US8193378B2 (pl)
EP (1) EP2354134B1 (pl)
JP (1) JP5578083B2 (pl)
KR (1) KR101589332B1 (pl)
CN (1) CN102239164B (pl)
AU (1) AU2009323259A1 (pl)
BR (1) BRPI0922135B1 (pl)
CA (1) CA2745356C (pl)
ES (1) ES2570155T3 (pl)
IL (1) IL213261A0 (pl)
MX (1) MX2011005954A (pl)
PL (1) PL2354134T3 (pl)
RU (1) RU2490266C2 (pl)
WO (1) WO2010064707A1 (pl)
ZA (1) ZA201103928B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
CA2789480A1 (en) * 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
ES2379242B1 (es) * 2010-09-28 2013-03-04 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromeno.
EP2511275A1 (en) * 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
EP2697195A1 (en) * 2011-04-14 2014-02-19 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
KR20140048874A (ko) * 2011-04-14 2014-04-24 알러간, 인코포레이티드 스핑고신-1 포스페이트 수용체 조절제로서의 페닐 이환식 메틸 아민 유도체
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
WO2012145236A1 (en) * 2011-04-18 2012-10-26 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US20140235613A1 (en) * 2013-02-20 2014-08-21 Allergan, Inc. Substituted diaryl azetidine derivatives as sphingosine receptor modulators
EP2990055B1 (en) 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2534336B1 (es) * 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno como inhibidores de la interacción TCR-Nck
ES2534318B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
CN104650022B (zh) * 2013-11-20 2018-09-25 浙江奥翔药业股份有限公司 奈必洛尔的合成方法及其中间体化合物
CN105712893A (zh) * 2014-12-02 2016-06-29 重庆安格龙翔医药科技有限公司 一种3-氯-4-甲氧基苄胺的合成方法
CN105712891A (zh) * 2014-12-02 2016-06-29 重庆安格龙翔医药科技有限公司 制备高纯度3-氯-4-甲氧基苄胺的方法
WO2017202276A1 (zh) * 2016-05-23 2017-11-30 中国医学科学院药物研究所 苯醚类衍生物、及其制法和药物组合物与用途
US10752575B2 (en) 2016-07-29 2020-08-25 Mitsubishi Tanabe Pharma Corporation 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method
SG11202006255UA (en) * 2018-02-02 2020-07-29 Univ Kyoto Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
US10696663B2 (en) 2018-02-27 2020-06-30 Artax Biopharma Inc. Chromene derivatives as inhibitors of TCR-NCK interaction
HUE061248T2 (hu) * 2018-03-27 2023-06-28 Neuropore Therapies Inc Vegyületek TLR2 jelátvitel modulátoraiként
EP3825303A4 (en) 2018-07-17 2022-07-06 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
CN109824725B (zh) * 2019-03-11 2021-12-10 江西科技师范大学 一种4-磷酸酯-2h-色烯衍生物的制备方法
AU2020245489A1 (en) 2019-03-26 2021-10-14 Neuropore Therapies, Inc. Compounds and compositions as modulators of tlr signaling
CA3135344A1 (en) 2019-03-29 2020-10-08 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
CN114761401A (zh) 2019-12-03 2022-07-15 株式会社Lg化学 鞘氨醇-1-磷酸受体激动剂、其制备方法以及含有它作为活性成分的药物组合物
WO2021160680A1 (en) * 2020-02-11 2021-08-19 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
EP4306516A4 (en) * 2021-04-14 2024-09-11 Lg Chem, Ltd. NEW METHOD FOR THE PRODUCTION OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST
WO2022220611A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 신규한 제조방법
WO2022220610A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법
WO2025137442A1 (en) * 2023-12-22 2025-06-26 Artax Biopharma Inc. SOLID AND SALT FORMS OF TCR-NcK MODULATORS AND USES THEREOF

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3807813A1 (de) * 1988-03-10 1989-09-21 Thomae Gmbh Dr K Neue benzocycloheptenderivate, diese verbindungen enthaltende arzneimittel und verfahren zu deren herstellung
ES2098186B1 (es) * 1995-02-09 1998-02-01 Consejo Superior Investigacion Composiciones farmaceuticas a base de aminometilindoles para su aplicacion terapeutica como neuroprotectores en las enfermedades de parkinson y alzheimer.
HU225960B1 (en) 1997-02-27 2008-01-28 Takeda Pharmaceutical Amine compounds, their production and use
JPH11106381A (ja) * 1997-09-30 1999-04-20 Ss Pharmaceut Co Ltd クロメン誘導体及びその塩並びにこれを含有する医薬
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
US7825109B2 (en) * 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
RU2390519C2 (ru) * 2003-08-29 2010-05-27 Оно Фармасьютикал Ко., Лтд. Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
RU2007109207A (ru) * 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
CN101115709B (zh) * 2004-12-13 2011-04-13 小野药品工业株式会社 氨基羧酸衍生物及其医药用途
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
WO2007092638A1 (en) * 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2007129473A1 (ja) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited 二環性アリール誘導体
WO2010051031A1 (en) * 2008-10-30 2010-05-06 Biogen Idec Ma Inc. Heterobicyclic sphingosine 1-phosphate analogs

Also Published As

Publication number Publication date
JP5578083B2 (ja) 2014-08-27
BRPI0922135A2 (pt) 2018-06-05
EP2354134A4 (en) 2012-08-29
AU2009323259A1 (en) 2011-06-23
ZA201103928B (en) 2012-08-29
MX2011005954A (es) 2011-10-11
WO2010064707A1 (ja) 2010-06-10
US20110230463A1 (en) 2011-09-22
CN102239164B (zh) 2013-10-30
US8193378B2 (en) 2012-06-05
KR101589332B1 (ko) 2016-01-27
IL213261A0 (en) 2011-07-31
CA2745356C (en) 2016-12-20
JPWO2010064707A1 (ja) 2012-05-10
CA2745356A1 (en) 2010-06-10
ES2570155T3 (es) 2016-05-17
BRPI0922135B1 (pt) 2021-07-13
EP2354134A1 (en) 2011-08-10
EP2354134B1 (en) 2016-02-24
US20120178735A1 (en) 2012-07-12
CN102239164A (zh) 2011-11-09
RU2490266C2 (ru) 2013-08-20
KR20110091865A (ko) 2011-08-16

Similar Documents

Publication Publication Date Title
PL2354134T3 (pl) Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny
HUS2000038I1 (hu) Szfingozin foszfát receptor új modulátorai
GB0818498D0 (en) Provision of inserts
IL211701A0 (en) Process for the preparation of bendamustine
PL2334761T3 (pl) Wytwarzanie wsadu do alkilowania
IL219692A0 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
IL209196A (en) A crystalline form of posaconazole
ZA201100102B (en) Hydrogenation of multi-brominated alkanes
IL209306A (en) Compounds 1, 2, 4 - Oxadiazole as modulators of sphingosine phosphate receptors
PL2151428T3 (pl) Nowy sposób syntezy agomelatyny
IL220187A0 (en) Inhibitors of sphingosine kinase
EP2445891A4 (en) 5-CHAIN HETEROARYL DERIVATIVES AS SPHINOSINE-1-PHOSPHATE RECEPTOR AGONISTS
EP2212251A4 (en) PROCESS FOR THE PRODUCTION OF CLUSTERBOR
ZA201005303B (en) An improved process for preparation of paliperidone
EG26332A (en) Process for the preparation of benzonoprons
SI2151429T1 (sl) Postopek za pripravo agomelatina
EP2205525A4 (en) PROCESS FOR THE PREPARATION OF CLUSTERBORON
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
IL208918A0 (en) Methods of preparing substituted heterocycles-149
EP2445892A4 (en) 5-LOW HETEROARYL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS
IL212902A0 (en) Method of preparing deoxyribofuranose compounds
IL211382A0 (en) Process for the preparation of ethanedinitrile
EP2250178A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF TRIAZOL-BENZODIAZEPINE DERIVATIVES
EP2398491A4 (en) ANTAGONISM OF SPHINGOSINE 1-PHOSPHATE
GB0812613D0 (en) Process for the preparation of 1-deoxyidonojirimycin